The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

CHRS FINANCIAL STATEMENTS

Coherus BioSciences Inc — balance sheet, income statement and cash flow trends

CHRSCoherus BioSciences Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-250 M0250 M500 M202020212022202320252026

Profit Funnel

Q2 2026 · TTM
Revenue50.9 M $Gross Profit32.4 M $ · 64%Operating Income-156.6 M $ · -307%Pre-tax Income-161.1 M $ · -316%Net Income to Owners-131 M $ · -257%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue50.9 M $-64.3%
Gross Profit32.4 M $-59.6%
Operating Income-156.6 M $—
EBITDA-148.5 M $—
Net Income to Owners-131 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0500 M202020212022202320252026

Capital Structure

Q2 2026
Total Assets191.2 M
  • Equity60.8 M $32%
  • Current Liabilities75.5 M $39%
  • Long-term Liabilities54.8 M $29%

Key Figures

YoY change
Total Assets191.2 M $-56.5%
Total Liabilities130.3 M $-59.2%
Total Equity60.8 M $-49.2%
Cash & ST Investments105.3 M $-55.7%
Total Debt37.7 M $-8.1%
Net Debt-45.2 M $—

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-200 M0202020212022202320252026

Cash Flow Bridge

Q2 2026 · TTM
-200 M-100 M0-243.9 M $Operating20.9 M $Investing115.4 M $Financing-107.6 M $Net Change

Key Figures

YoY change
Operating Cash Flow-243.9 M $—
Capital Expenditures0 $—
Free Cash Flow-243.9 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on CHRS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 23, 26. This content is for informational purposes only and is not investment advice.